Treatment of Severe Refractory Thrombocytopenia in Brucellosis With Eltrombopag

2021 ◽  
Author(s):  
Xianwen Zhang ◽  
Peng Ren ◽  
Baohua Sang ◽  
Chunyan Song ◽  
Yunbi Lin ◽  
...  
Keyword(s):  
Platelet Count ◽  
Intravenous Immunoglobulin ◽  
Successful Treatment ◽  
Steroid Treatment ◽  
Chinese Patients ◽  
Second Line ◽  
Case Presentation ◽  
Mild Anemia ◽  
The World

Abstract Background: Brucellosis is a common zoonotic illness in the world. Brucellosis is often characterized by hematologic abnormalities, including mild anemia, leukopenia, thrombocytopenia, or pancytopenia. However, severe refractory thrombocytopenia in brucellosis is very rare and easily misdiagnosed.Case presentation: The patient was a 5-year-old girl with brucellosis who developed severe refractory thrombocytopenia (platelet count: 3×109/L) with complaints of epistaxis, skin petechiae and purpura. Most conventional treatments including glucocorticoids and intravenous immunoglobulin (IVIg) did not elevate her platelets, but eltrombopag worked well and her platelet count recovered rapidly. One week later, the patient's symptoms improved and the platelet count returned to normal.Conclusions:Patients with severe refractory thrombocytopenia, particularly resistant to IVIg and steroid treatment should be considered for second-line drugs such as eltrombopag. Our results also increase the application experience of eltrombopag in Chinese patients with severe refractory thrombocytopenia in brucellosis. To the best of our knowledge, this case is the first reported case of the successful treatment of severe refractory thrombocytopenia in brucellosis with eltrombopag.

scholarly journals Romiplostim: Successful treatment of a pregnant woman with refractory immune thrombocytopenia

2018 ◽  
Vol 5 (8) ◽  
pp. 2565-2571
Author(s):  
Mehrdad Payandeh ◽  
Afshin Karami ◽  
Noorodin Karami ◽  
Jafar Barati Masgareh
Keyword(s):  
Platelet Count ◽  
Pregnant Woman ◽  
Successful Treatment ◽  
Immune Thrombocytopenia ◽  
Response To Treatment ◽  
Line Treatment ◽  
Second Line ◽  
Fetal Complications ◽  
Adults And Children

Immune thrombocytopenia is characterized by reduced platelet count. This condition occurs in both adults and children. The most common form of thrombocytopenia is primary ITP and autoantibodies are involved in its development. In this study, our patient was a pregnant woman with ITP who showed refractory to prednisolone and splenectomy as first and second line treatment, respectively, but the response to treatment with Romiplostim and platelet count was favorable, and delivery was reported without fetal complications.

scholarly journals Immediate hypersensitivity reaction followed by successful oral desensitization to ursodiol

2021 ◽  
Vol 17 (1) ◽  
Author(s):  
Erika Yue Lee ◽  
Christine Song
Keyword(s):  
Hypersensitivity Reaction ◽  
Primary Biliary Cholangitis ◽  
Line Treatment ◽  
Second Line ◽  
Immediate Hypersensitivity ◽  
First Line ◽  
Case Presentation ◽  
Desensitization Protocol ◽  
First Line Treatment ◽  
Oral Desensitization

Abstract Background Immediate hypersensitivity reaction to ursodiol is rare and there is no previously published protocol on ursodiol desensitization. Case presentation A 59-year-old woman with primary biliary cholangitis (PBC) developed an immediate hypersensitivity reaction to ursodiol—the first-line treatment for PBC. When she switched to a second-line treatment, her PBC continued to progress. As such, she completed a novel 12-step desensitization protocol to oral ursodiol. She experienced recurrent pruritus after each dose following desensitization, which subsided after a month of being on daily ursodiol. Conclusion Immediate hypersensitivity reaction to ursodiol is uncommon. Our case demonstrated that this novel desensitization protocol to ursodiol could be safely implemented when alternative options are not available or have proven inferior in efficacy.

scholarly journals Cerebral venous thrombosis in a patient with Down syndrome and coronavirus disease 2019: a case report

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Henry Robayo-Amortegui ◽  
Natalia Valenzuela-Faccini ◽  
Cesar Quecano-Rosas ◽  
Darlyng Zabala-Muñoz ◽  
Michel Perez-Garzon
Keyword(s):  
Risk Factors ◽  
Down Syndrome ◽  
Case Report ◽  
Venous Thrombosis ◽  
Cerebral Venous Thrombosis ◽  
Epidemiological Data ◽  
Thromboembolic Disease ◽  
Hispanic Woman ◽  
Case Presentation ◽  
The World

Abstract Background The new coronavirus disease 2019 pandemic has spread throughout most of the world. Cerebral venous thrombosis is a rare thromboembolic disease that can present as an extrapulmonary complication in coronavirus disease 2019 infection. Case presentation We report the case of a Hispanic woman with Down syndrome who has coronavirus disease 2019 and presents as a complication extensive cerebral venous thrombosis. Conclusions Cerebral venous thrombosis is a rare thromboembolic disease that can present as an extrapulmonary complication in coronavirus disease 2019 infection. In the absence of clinical and epidemiological data, it is important to carry out further investigation of the risk factors and pathophysiological causes related to the development of cerebrovascular thrombotic events in patients with Down syndrome with coronavirus disease 2019 infection.

scholarly journals Successful treatment of acquired reactive perforating collagenosis with itraconazole

2021 ◽  
Vol 26 (1) ◽  
Author(s):  
Binrong Ye ◽  
Yi Cao ◽  
Yeqiang Liu
Keyword(s):  
Skin Biopsy ◽  
Fungal Infection ◽  
Successful Treatment ◽  
Rare Form ◽  
Case Presentation ◽  
Therapeutic Benefits ◽  
Immunological Tests ◽  
Anti Inflammatory ◽  
Reactive Perforating Collagenosis

Abstract Background Acquired reactive perforating collagenosis (ARPC) is a rare form of transepithelial elimination in which altered collagen is extruded through the epidermis. Case presentation A 23-year-old male presented with cup-like ulcerated lesions on his limbs since 3 months. A series of serological and immunological tests showed no abnormalities. A diagnosis of ARPC was based on skin biopsy findings. The patient was cured using treatment with itraconazole for 8 weeks, in the absence of a fungal infection. Conclusions The anti-inflammatory and anti-angiogenic effects of itraconazole can have good therapeutic benefits for ARPC.

Optimizing Second-Line Therapy for Hodgkin Lymphoma: A Work in Progress

2021 ◽  
pp. JCO.21.01552
Author(s):  
Nancy L. Bartlett
Keyword(s):  
Clinical Practice ◽  
Hodgkin Lymphoma ◽  
Relevant Literature ◽  
Second Line ◽  
Clinical Context ◽  
Second Line Therapy ◽  
Case Presentation ◽  
Line Therapy ◽  
Management Approaches ◽  
Grand Rounds

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.

Successful treatment of infliximab-associated immune-mediated sensory polyradiculopathy with intravenous immunoglobulin

2013 ◽  
Vol 20 (11) ◽  
pp. 1618-1619 ◽  
Author(s):  
Hiroya Naruse ◽  
Yu Nagashima ◽  
Risa Maekawa ◽  
Takafumi Etoh ◽  
Ayumi Hida ◽  
...  
Keyword(s):  
Intravenous Immunoglobulin ◽  
Successful Treatment ◽  
Immune Mediated
Sign in / Sign up

Export Citation Format

Share Document